Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul;147(7):2035-2045.
doi: 10.1007/s00432-021-03629-z. Epub 2021 Apr 22.

Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review

D Huber #  1 , S Seitz #  1 , K Kast  2 , G Emons  3 , O Ortmann  4
Affiliations

Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review

D Huber et al. J Cancer Res Clin Oncol. 2021 Jul.

Abstract

Purpose: BRCA mutation carriers have an increased risk of developing breast or ovarian cancer. Risk-reducing bilateral salpingo-oophorectomy (RRBSO) is associated with a decrease in risk for tubal and ovarian cancer. Hormone replacement therapy (HRT) may increase breast, ovarian, and endometrial cancer risk in the general population. This review analyses the published data on HRT and risk of cancer in BRCA mutation carriers with and without RRBSO.

Methods: We included all relevant articles published in English from 1995 to October 2020. Sources were identified through a search on PubMed and Cochrane Library.

Results: We included one case-control and one retrospective cohort study on ovarian and one case-control study on endometrial cancer risk and HRT in BRCA mutation carriers. Regarding breast cancer risk, one case-control study on BRCA mutation carriers with and without RRBSO and one case-control study, one Markov chain decision model, two prospective cohort studies, and one metaanalysis on carriers after RRBSO were included. For ovarian cancer, results were ambiguous. For breast cancer, most studies did not find an adverse effect associated with HRT. However, some of the studies found a risk modification associated with different formulations and duration of use.

Conclusion: Although data are limited, HRT does not seem to have a relevant effect on cancer risk in BRCA mutation carriers. RRBSO should not be postponed to avoid subsequent HRT in this population. Adequate HRT after RRBSO should be offered to avoid chronic diseases resulting from low estrogen levels. However, further data on the safety of different formulations are needed.

Keywords: BRCA1; BRCA2; Breast cancer; Hormone replacement therapy; Ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

    1. Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B (2004) Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J ClinOncol 22(6):1045–1054 - PubMed
    1. Beral V, Bull D, Reeves G (2005) Endometrial cancer and hormone-replacement therapy in the million women study. Lancet 365(9470):1543–1551 - PubMed
    1. Birrer N, Chinchilla C, Del Carmen M, Dizon DS (2018) Is hormone replacement therapy safe in women with a BRCA mutation?: A systematic review of the contemporary literature. Am J ClinOncol 41(3):313–315 - PubMed
    1. Collaborative Group on Hormonal Factors in Breast Cancer (2019) Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet 394(10204):1159–1168 - PMC - PubMed
    1. Domchek S, Kaunitz AM (2016) Use of systemic hormone therapy in BRCA mutation carriers. Menopause 23(9):1026–1027 - PubMed

Publication types